$82.66
Today
as of Jul 22, 16:46 ET
Last 30 days
Recent Press Releases & News
BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
How a Rival's Clinical Setback Sent BBIO Stock to a 52-Week High
Overview
52-week range
$38
$85
95% of range
Avg surprise (last 3)
-7.5%
Avg reaction (last 2)
+0.3%
50% positive
Latest IV / EM
49%
EM ±11.3% · $83 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.84 | $-0.70 | -20.0% | +4.5% | -0.9% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.95 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $-0.95 | $-0.83 | -14.5% | — | — | earnings |
| Tue Apr 29, 2025 | Mar/2025 | $-0.88 | $1.00 | +12.0% | — | +1.5% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.86 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.39 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.20 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-1.08 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.98 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 4, 2026 | Jun/2026 | OTHER | -$0.64 | -$0.95 | +32.6% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $195M | — | $121M | $111M | $117M | — | $3M | $2M |
| Cost of revenue | $10M | — | $7M | $4M | $3M | — | $598,000 | $598,000 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-106M | — | $-145M | $-134M | $-104M | — | $-192M | $-176M |
| Net income | — | — | — | — | — | — | — | — |
| EPS (diluted) | $-0.84 | — | $-0.95 | $-0.95 | $-0.88 | — | $-0.86 | $-0.39 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $880M | $570M | $643M | $749M | $541M | $681M | $266M | $408M |
| Inventory | $33M | $27M | $25M | $18M | $4M | $0 | — | — |
| Total current assets | $1.24B | $798M | $839M | $912M | $695M | $721M | $445M | $616M |
| Total assets | $1.37B | $936M | $998M | $1.08B | $882M | $919M | $665M | $794M |
| Long-term debt | — | — | — | $0 | $0 | $437M | $436M | $435M |
| Total liabilities | $3.64B | $3.01B | $2.92B | $2.86B | $2.52B | $2.38B | $1.88B | $1.88B |
| Total equity | $-2.28B | $-2.09B | $-1.93B | $-1.79B | $-1.65B | $-1.47B | $-1.23B | $-1.09B |